Mark W Skinner

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2842279/publications.pdf

Version: 2024-02-01

48	1,039	394421	454955
papers	citations	19 h-index	30 g-index

50	50	50	854
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	WFH: Closing the global gap â€“ achieving optimal care. Haemophilia, 2012, 18, 1-12.	2.1	86
2	Core outcome set for gene therapy in haemophilia: Results of the core<scp>HEM</scp> multistakeholder project. Haemophilia, 2018, 24, e167-e172.	2.1	74
3	The role of telemedicine in the delivery of health care in the COVIDâ€19 pandemic. Haemophilia, 2020, 26, e230-e231.	2.1	57
4	Achieving the unimaginable: Health equity in haemophilia. Haemophilia, 2020, 26, 17-24.	2.1	54
5	NHFâ€McMaster Guideline on Care Models for Haemophilia Management. Haemophilia, 2016, 22, 6-16.	2.1	50
6	The World Federation of Hemophilia Annual Global Survey 1999â€2018. Haemophilia, 2020, 26, 591-600.	2.1	50
7	Hemophilia trials in the twentyâ€first century: Defining patient important outcomes. Research and Practice in Thrombosis and Haemostasis, 2019, 3, 184-192.	2.3	42
8	Treatment for all: a vision for the future. Haemophilia, 2006, 12, 169-173.	2.1	36
9	The Patient Reported Outcomes, Burdens and Experiences (PROBE) Project: development and evaluation of a questionnaire assessing patient reported outcomes in people with haemophilia. Pilot and Feasibility Studies, 2018, 4, 58.	1.2	34
10	Riskâ€based decision making and ethical considerations in donor compensation for plasmaâ€derived medicinal products. Transfusion, 2016, 56, 2889-2894.	1.6	33
11	Genotypes, phenotypes and whole genome sequence: Approaches from the My Life Our Future haemophilia project. Haemophilia, 2018, 24, 87-94.	2.1	32
12	The 1st <scp>WFH</scp> Gene Therapy Round Table: Understanding the landscape and challenges of gene therapy for haemophilia around the world. Haemophilia, 2019, 25, 189-194.	2.1	31
13	Haemophilia: provision of factors and novel therapies: World Federation of Hemophilia goals and achievements. British Journal of Haematology, 2011, 154, 704-714.	2.5	28
14	World Federation of Hemophilia Gene Therapy Registry. Haemophilia, 2020, 26, 563-564.	2.1	28
15	Evidence of a disability paradox in patientâ€reported outcomes in haemophilia. Haemophilia, 2021, 27, 245-252.	2.1	25
16	Core data set on safety, efficacy, and durability of hemophilia gene therapy for a global registry: Communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2020, 18, 3074-3077.	3.8	24
17	Gene therapy to cure haemophilia: Is robust scientific inquiry the missing factor?. Haemophilia, 2020, 26, 931-933.	2.1	24
18	Gene Therapy for Hemophilia: Addressing the Coming Challenges of Affordability and Accessibility. Molecular Therapy, 2013, 21, 1-2.	8.2	23

#	Article	IF	Citations
19	WFH â€“ the cornerstone of global development: 45Âyears of progress. Haemophilia, 2008, 14, 1-9.	2.1	21
20	The effect of emicizumab prophylaxis on longâ€term, selfâ€reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies. Haemophilia, 2021, 27, 854-865.	2.1	21
21	Integrated Hemophilia Patient Care via a National Network of Care Centers in the United States: A Model for Rare Coagulation Disorders. Journal of Blood Medicine, 2021, Volume 12, 897-911.	1.7	21
22	Patientâ€relevant health outcomes for hemophilia care: Development of an international standard outcomes set. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12488.	2.3	20
23	Establishing the appropriate primary endpoint in haemophilia gene therapy pivotal studies. Haemophilia, 2017, 23, 643-644.	2.1	18
24	Cell Phones and Landlines: The Impact of Gene Therapy on the Cost and Availability of Treatment for Hemophilia. Molecular Therapy, 2011, 19, 1749-1750.	8.2	16
25	Nonâ€severe haemophilia: Is it benign? â€“ Insights from the PROBE study. Haemophilia, 2021, 27, 17-24.	2.1	16
26	Psychometric properties of the Patient Reported Outcomes, Burdens and Experiences (PROBE) questionnaire. BMJ Open, 2018, 8, e021900.	1.9	15
27	Patient preferences and priorities for haemophilia gene therapy in the US: A discrete choice experiment. Haemophilia, 2021, 27, 769-782.	2.1	15
28	Testâ€retest properties of the Patient Reported Outcomes, Burdens and Experiences (PROBE) questionnaire and its constituent domains. Haemophilia, 2019, 25, 75-83.	2.1	14
29	Evolution of haemophilia integrated care in the era of gene therapy: Treatment centreâ€™s readiness in United States and EU. Haemophilia, 2021, 27, 511-514.	2.1	13
30	Eliminating Panglossian thinking in development of AAV therapeutics. Molecular Therapy, 2021, 29, 3325-3327.	8.2	12
31	The Hemophilia Gene Therapy Patient Journey: Questions and Answers for Shared Decision-Making. Patient Preference and Adherence, 0, Volume 16, 1439-1447.	1.8	12
32	Building our global family â€“ achieving treatment for all. Haemophilia, 2010, 16, 1-10.	2.1	11
33	Haemophilia care â€“ past, present and future from a patient perspective. Haemophilia, 2012, 18, 3-5.	2.1	11
34	Exploring regional variations in the crossâ€cultural, international implementation of the Patient Reported Outcomes Burdens and Experience (PROBE) study. Haemophilia, 2019, 25, 365-372.	2.1	11
35	World Federation of Hemophilia: 50Âyears of advancing treatment for all. Haemophilia, 2013, 19, 475-480.	2.1	9
36	Vaccination against COVIDâ€19: Rationale, modalities and precautions for patients with haemophilia and other inherited bleeding disorders. Haemophilia, 2021, 27, 515-518.	2.1	9

#	Article	IF	Citations
37	Identified unmet needs and proposed solutions in mildâ€toâ€moderate haemophilia: A summary of opinions from a roundtable of haemophilia experts. Haemophilia, 2021, 27, 25-32.	2.1	9
38	Assessments of outcome in haemophilia â€“ a patient perspective. Haemophilia, 2016, 22, e208-9.	2.1	8
39	A preliminary application of a haemophilia value framework to emerging therapies in haemophilia. Haemophilia, 2022, 28, 9-18.	2.1	8
40	Challenges and key lessons from the design and implementation of an international haemophilia registry supported by a pharmaceutical company. Haemophilia, 2020, 26, 966-974.	2.1	4
41	Improving comprehensive care in the haemophilia community: building on the <scp>HERO</scp> Study. Haemophilia, 2016, 22, e320-2.	2.1	3
42	The national haemophilia program standards, evaluation and oversight systems in the United States of America. Blood Transfusion, 2014, 12 Suppl 3, e542-8.	0.4	3
43	Ensuring maximum outcomes and benefits in comprehensive care for bleeding disorders through surveillance and data collection. Hematology, 2012, 17, s147-s149.	1.5	2
44	Evaluation of the sexual health in people living with hemophilia. Haemophilia, 2021, 27, 993-1001.	2.1	2
45	Examination and Validation of a Patient-Centric Joint Metric: "Problem Joint"; Empirical Evidence from the CHESS US Dataset. Blood, 2020, 136, 25-26.	1.4	2
46	User-Centered Development and Testing of the Online Patient-Reported Outcomes, Burdens, and Experiences (PROBE) Survey and the myPROBE App and Integration With the Canadian Bleeding Disorder Registry: Mixed Methods Study. JMIR Human Factors, 2022, 9, e30797.	2.0	2
47	Test-Retest Reliability Analysis of the Patient Reported Outcomes Burdens and Experiences (PROBE). Blood, 2016, 128, 5964-5964.	1.4	0
48	Association of factor expression levels with health-related quality of life and direct medical costs for people with haemophilia B. Journal of Medical Economics, 2022, 25, 386-392.	2.1	0